Compare
Lite Strategy, Inc. vs Cue Biopharma, Inc. vs BioXcel Therapeutics, Inc. vs Medicinova Inc
| Latest fiscal year | Lite Strategy, Inc. LITS | Cue Biopharma, Inc. CUE | BioXcel Therapeutics, Inc. BTAIQ | Medicinova Inc MNOV |
|---|---|---|---|---|
| Year ended | 2026-06-30 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $27.47M | $642.0K | $409.7K |
| Revenue growth (YoY) | n/a | +195.7% | -71.7% | n/a |
| Gross margin | n/a | n/a | 74.5% (computed) | n/a |
| Operating margin | n/a | -96.7% | n/m | n/m |
| Net margin | n/a | -96.9% | n/m | n/m |
| Net income | -$71.15M | -$26.60M | -$69.90M | -$12.00M |
| EPS (Diluted) | -$2.06 | -$0.28 | -$5.73 | -$0.24 |
| Operating cash flow | -$9.12M | -$21.69M | -$57.62M | -$9.81M |
| Free cash flow | n/a | -$21.86M | -$57.62M | -$9.81M |
| Cash & equivalents | $5.71M | $27.14M | $28.41M | $30.81M |
| Total assets | $42.69M | $42.21M | $44.92M | $45.60M |
| Total liabilities | $1.07M | $15.78M | $140.38M | $4.02M |
| Shareholders' equity | $41.62M | $26.43M | -$95.46M | $41.59M |
| Return on year-end equity | -170.9% | -100.6% | n/a | -28.9% |
| Shares outstanding | 32.41M | 96.62M | 22.33M | 49.22M |
Revenue, most recent five fiscal years
| Fiscal year | Lite Strategy, Inc. | Cue Biopharma, Inc. | BioXcel Therapeutics, Inc. | Medicinova Inc |
|---|---|---|---|---|
| Latest | $0 Ended 2025-06-30 | $27.47M Ended 2025-12-31 | $642.0K Ended 2025-12-31 | $409.7K Ended 2025-12-31 |
| 1 year earlier | $65.30M Ended 2024-06-30 | $9.29M Ended 2024-12-31 | $2.27M Ended 2024-12-31 | n/a |
| 2 years earlier | $48.82M Ended 2023-06-30 | $5.49M Ended 2023-12-31 | $1.38M Ended 2023-12-31 | $1.00M Ended 2023-12-31 |
| 3 years earlier | $40.70M Ended 2022-06-30 | $1.25M Ended 2022-12-31 | $375.0K Ended 2022-12-31 | n/a |
| 4 years earlier | $34.80M Ended 2021-06-30 | $14.94M Ended 2021-12-31 | n/a | $4.04M Ended 2021-12-31 |